CDK4 and breast cancer: Though not specifically analyzing ER+ breast cancer, one study using patient-derived xenografts (PDX) of melanoma to analyze resistance to CDK4/6 inhibitors determined that the PI3K–AKT pathway was activated in the intrinsically resistant models [52].